K-V Complaint Over Compound Medicine Rejected by U.S. Trade Body
This article is for subscribers only.
K-V Pharmaceutical Co., a bankrupt maker of women’s health-care products, lost its bid to use a U.S. trade agency to keep competitors from importing versions of a medicine that prevents premature births, after federal drug regulators had refused to stop them.
The U.S. International Trade Commission in Washington, which has the power to block imports, said yesterday it wouldn’t investigate a complaint K-V filed in October. K-V, which blamed lax federal enforcement for its bankruptcy, claims the companies are violating exclusivity rules for the active ingredient in its Makena treatment.